TRKC (G623E)

NTRK3 · Variant type: point · HGVS: p.G623E

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	92.0%	8.0%	78.23
2	Entrectinib	72.7%	27.3%	93.69
3	Repotrectinib	63.6%	36.4%	84.21
4	Ripretinib	52.7%	47.3%	92.95
5	Nilotinib	48.5%	51.5%	96.49
6	Tivozanib	47.8%	52.2%	92.42
7	Cabozantinib	45.1%	54.9%	92.73
8	Darovasertib	39.2%	60.8%	96.99
9	Pralsetinib	38.8%	61.2%	93.43
10	Pexidartinib	35.2%	64.8%	99.49
11	Alpelisib	28.0%	72.0%	97.22
12	Brigatinib	24.3%	75.8%	82.96
13	Pacritinib	22.9%	77.1%	88.64
14	Defactinib	22.7%	77.3%	92.68
15	Upadacitinib	16.5%	83.5%	97.98
16	Apatinib	15.2%	84.8%	97.73
17	Capmatinib	14.8%	85.2%	99.75
18	Vandetanib	14.0%	86.0%	95.74
19	Erdafitinib	13.9%	86.1%	95.71
20	Futibatinib	13.7%	86.3%	98.48
21	Quizartinib	13.6%	86.4%	99.50
22	Paxalisib	13.6%	86.4%	99.75
23	Sunitinib	13.6%	86.4%	91.73
24	Neratinib	13.2%	86.8%	93.18
25	Selpercatinib	12.8%	87.2%	96.72

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	92.0%	96.7%	-4.7%
Entrectinib	72.7%	98.8%	-26.1%
Repotrectinib	63.6%	98.9%	-35.3%
Ripretinib	52.7%	—	—
Nilotinib	48.5%	—	—
Tivozanib	47.8%	96.1%	-48.3%
Cabozantinib	45.1%	—	—
Darovasertib	39.2%	94.5%	-55.3%
Pralsetinib	38.8%	99.4%	-60.7%
Pexidartinib	35.2%	—	—
Alpelisib	28.0%	99.3%	-71.2%
Brigatinib	24.3%	—	—
Pacritinib	22.9%	96.7%	-73.8%
Defactinib	22.7%	91.7%	-69.0%
Upadacitinib	16.5%	—	—
Apatinib	15.2%	—	—
Capmatinib	14.8%	—	—
Vandetanib	14.0%	—	—
Erdafitinib	13.9%	—	—
Futibatinib	13.7%	—	—
Quizartinib	13.6%	—	—
Paxalisib	13.6%	—	—
Sunitinib	13.6%	95.4%	-81.7%
Neratinib	13.2%	—	—
Selpercatinib	12.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.4ms